ID
12148
Description
An open-label, multicenter, randomized, comparative, phase III study to evaluate the efficacy and safety of rituximab plus fludarabine and cyclophosphamide (FCR) versus fludarabine and cyclophosphamide alone (FC) in previously treated patients with CD20 positive B-cell chronic lymphocytic leukemia (CLL).
Keywords
Versions (3)
- 9/30/15 9/30/15 -
- 10/28/15 10/28/15 -
- 9/27/21 9/27/21 -
Uploaded on
September 30, 2015
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0 Legacy
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
CLL Completion NCT00090051 BO17072
Treatment phase completion Chronic Lymphocytic Leukemia NCT00090051 BO17072
Description
Treatment phase completion
Description
Date of last dosing
Data type
date
Measurement units
- dd/mm/yy
Alias
- UMLS CUI [1,1]
- C0011008
- UMLS CUI [1,2]
- C1762893
Description
Study completion
Data type
boolean
Description
Reason for no completion
Data type
integer
Description
Specify violation of selection criteria
Data type
text
Description
Specify other protocol violation
Data type
text
Description
Specify other reason
Data type
text
Description
Additional observations
Alias
- UMLS CUI-1
- C1524062
Similar models
Treatment phase completion Chronic Lymphocytic Leukemia NCT00090051 BO17072
C0007465 (UMLS CUI [1,2])
C1306577 (UMLS CUI [1,2])
C1762893 (UMLS CUI [1,2])